Immix Biopharma Inc. (IMMX)
Company Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia.
The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab.
The company was incorporated in 2012 and is headquartered in Los Angeles, California.
| Country | United States |
| IPO Date | Dec 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. |
Contact Details
Address: 11400 West Olympic Boulevard Los Angeles, California United States | |
| Website | https://www.immixbio.com |
Stock Details
| Ticker Symbol | IMMX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001873835 |
| CUSIP Number | 45258H106 |
| ISIN Number | US45258H1068 |
| Employer ID | 45-4869378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | Co-Founder, Chief Executive Officer & Chairman |
| Gabriel Morris B.A. | Chief Financial Officer & Director |
| Dr. David Marks MBBS, Ph.D. | Chief Medical Officer of Cell Therapy |
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer & Head of Clinical Development |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder |
| Gerhard Bauer | Head of Cell Therapy Manufacturing |
| Sean Senn J.D., M.B.A., M.Sc., MBA, MSc | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 03, 2025 | 424B5 | Filing |
| Jun 03, 2025 | 8-K | Current Report |
| May 19, 2025 | ARS | Filing |
| May 19, 2025 | 10-Q/A | [Amend] Quarterly Report |
| May 19, 2025 | DEFA14A | Filing |
| May 19, 2025 | 10-K/A | [Amend] Annual Report |
| May 08, 2025 | 10-Q | Quarterly Report |
| May 05, 2025 | DEFA14A | Filing |
| Apr 30, 2025 | DEF 14A | Filing |
| Mar 25, 2025 | 10-K | Annual Report |